Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M32.0Revenue (TTM) $M0.0Net Margin (%)-35,983.3Altman Z-Score-49.5
Enterprise Value $M20.1EPS (TTM) $-0.7Operating Margin %-35,983.3Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-35,983.3Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %-18.8Quick Ratio3.3Cash flow > EarningsY
Price/Sales4455-y EBITDA Growth Rate %-5.6Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-123.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-149.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

RPRX is held by these investors:



RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-12-09Buy20,000$1.6-44.38view
Masterson Nola EDirector 2016-11-21Sell3,305$1.95-54.36view
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.93-4.3view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.18-24.58view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-90.54view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-90.55view
Masterson Nola EDirector 2014-09-15Buy200$14.34-93.79view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-93.6view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-93.57view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-94.05view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Apr 17 2017 
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017 
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017 
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017 
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 

More From Other Websites
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For... Apr 17 2017
Repros' Proellex Continues to be Under Partial Clinical Hold Apr 11 2017
Woodlands drug company names new top exec Apr 11 2017
Repros Therapeutics stock halted after FDA says partial clinical hold will continue for fibroids... Apr 10 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017
Repros Therapeutics reports 4Q loss Mar 31 2017
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017
Repros (RPRX) Q4 Earnings: What's in Store for the Stock? Mar 07 2017
Repros Announces New CEO Feb 02 2017
FDA Grants End of Phase 2 Meeting to Discuss Phase 3 Requirements for Oral Proellex® in the... Jan 30 2017
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016
7 Companies That Destroyed Shareholders Last Week Dec 10 2016
Repros Therapeutics Drops on FDA Vote Dec 07 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)